UFP Technologies, Inc. (UFPT) SEC Filings & Earnings Calls
EquiReason read 19 UFP Technologies, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-24 — UFP Technologies filed an 8-K with updated investor presentation materials; no material operational or financial event disclosed..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.3B
- P/E TTM
- 31.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
24 Aug 20268-K · 7.01UFP Technologies filed an 8-K with updated investor presentation materials; no material operational or financial event disclosed.open
Risks flagged
No new risk signals; standard forward-looking statement risks.
“Boilerplate risk factors in presentation.”
6 Aug 202610-QQ2 2026 earnings result with 9.6% net sales growth and 12.4% organic growth, but with operational headwinds from AJR labor issue and tariff uncertainty.earningsopen
Figures in the filing · each found in the filing text
| Net sales · H1-2026 | $328M | +10% y/y |
| Organic sales growth · Q2-2026 | 12.4% |
Risks flagged
Customer concentration
“Net sales from our largest two customers were 26.2% and 21.0% of our total net sales during the three months ended June 30, 2026” · word for word
Tariff uncertainty
“Given that the tariff landscape created by the current administration remains dynamic, we continue to adapt to the changes and manage new requirements.” · word for word
Operational disruption from AJR Labor Issue
“Attention spent by experienced employees training new direct and indirect employees in our standards and policies has decreased productivity and therefore has created inefficiencies in our AJR operations.” · word for word
3 Aug 20268-K · 2.02Net sales $174M (+15% y/y); Net income $21M (+21% y/y); GAAP diluted EPS $2.68 (+21% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $174M | +15% y/y |
| Net income · Q2-2026 | $21M | +21% y/y |
| GAAP diluted EPS · Q2-2026 | $2.68 | +21% y/y |
| Adjusted diluted EPS · Q2-2026 | $2.92 | +17% y/y |
| Gross margin · Q2-2026 | 29.3% | |
| Adjusted EBITDA · Q2-2026 | $36M | +14% y/y |
Risks flagged
Investments in Dominican Republic operations causing near-term margin pressure.
“Investments are creating near-term mix and margin pressure within our U.S. operations.” · word for word
SG&A increasing faster than sales, impacting operating leverage.
“SG&A increased 21.8% to $22.8 million; as a percentage of sales, SG&A increased to 13.1% from 12.4%.” · word for word
8 May 202610-QNet sales $154M (+4% y/y); Medical market revenue growth 5.9; Customer concentration - Stryker 24.8open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $154M | +4% y/y |
| Medical market revenue growth · medical · Q1-2026 | 5.9% | |
| Customer concentration - Stryker · Q1-2026 | 24.8% | |
| Customer concentration - Intuitive Surgical · Q1-2026 | 22.1% |
Risks flagged
Customer concentration risk
“Net sales from our largest two customers, Stryker and Intuitive Surgical SARL, were 24.8% and 22.1% of our total net sales” · word for word
Operational disruption from labor issue
“Attention spent by experienced employees training new direct and indirect employees in our standards and policies has decreased productivity and therefore has created inefficiencies in our AJR operations.” · word for word
Cyber incident risk
“On or about February 14, 2026, we detected the Cyber Incident” · word for word
4 May 20268-K · 2.02Net sales $154M (+4% y/y); Net income $17M (+2% y/y); Adjusted diluted EPS $2.48 (+0% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · consolidated · Q1-2026 | $154M | +4% y/y |
| Net income · consolidated · Q1-2026 | $17M | +2% y/y |
| Adjusted diluted EPS · consolidated · Q1-2026 | $2.48 | +0% y/y |
| GAAP diluted EPS · consolidated · Q1-2026 | $2.24 | +1% y/y |
| Medical sales · medical · Q1-2026 | $143M | +6% y/y |
| Non-medical sales · non-medical · Q1-2026 | $11M | -15% y/y |
| Gross margin · consolidated · Q1-2026 | 28.8% | |
| Adjusted EBITDA · consolidated · Q1-2026 | $31M | +3% y/y |
| Operating income · consolidated · Q1-2026 | $23M | +1% y/y |
| SG&A as % of sales · consolidated · Q1-2026 | 13.6% |
Risks flagged
E-Verify labor inefficiency costs at AJR operation
“Softer results at our AJR operation related to continued E-Verify labor inefficiency costs” · word for word
Start-up expenses for four large ramping programs
“Absorbed the start-up expenses associated with four large programs that are currently ramping” · word for word
Non-medical sales decline of 15%
“Non-medical sales decreased 15.0% to $10.8 million”
30 Apr 2026DEF 14AProxy statement for 2026 Annual Meeting of Stockholders.open
Figures in the filing · each found in the filing text
| Adjusted Operating Income · FY2025 | $98M | |
| Net income · FY2025 | $68M | |
| Total Shareholder Return (TSR) · FY2025 | $476.22 | |
| CEO total compensation (SCT) · FY2025 | $8M | |
| CEO compensation actually paid (CAP) · FY2025 | $8M | |
| CEO base salary · FY2025 | $789000.00 | |
| CEO target bonus percentage · FY2025 | 105.0% | |
| CEO actual bonus · FY2025 | $1M | |
| CEO stock awards grant date fair value · FY2025 | $5M | |
| CEO all other compensation · FY2025 | $221007.00 |
Risks flagged
CEO succession risk
“Effective as of June 4, 2026, Mr. Bailly will retire from his position as the Chief Executive Officer of the Company.” · word for word
Key person dependency
“Mr. Bailly has served as Chairman of the Board since October 2006 and as Chief Executive Officer and a director since January 1, 1995.” · word for word
Related party transaction risk
“In fiscal 2025, we paid Mr. Bailly’s brother, John Bailly, compensation in the aggregate amount of approximately $216,292” · word for word
Concentration of customer risk
“We are a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. We are a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers.” · word for word
International operations risk
“The CEO pay ratio calculation included 2,570 employees from Costa Rica and the Dominican Republic” · word for word
27 Feb 202610-KNet cash provided by operations $92M; Net income $68M; Depreciation and amortization $19Mopen
Figures in the filing · each found in the filing text
| Net cash provided by operations · FY2025 | $92M | |
| Net income · FY2025 | $68M | |
| Depreciation and amortization · FY2025 | $19M | |
| Share-based compensation · FY2025 | $9M | |
| Net cash used in investing activities · FY2025 | $28M | |
| Net cash used in financing activities · FY2025 | $58M | |
| Total long-term debt · 2025-12-31 | $135M | -29% y/y |
| Weighted average interest rate · 2025-12-31 | 5.1% | |
| Goodwill and other intangible assets · 2025-12-31 | $338M | |
| International net sales percentage · FY2025 | 16.0% |
Risks flagged
Tariff cost pressure on margins
“The U.S. government has also imposed tariffs on certain foreign goods. These measures may materially increase costs for goods imported into the United States. This in turn could require us to materially increase prices to our customers which may reduce demand, or, if we are unable to increase prices to adequately address any tariffs, quotas or duties result ” · word for word
Dollar strength impact on international revenue
“Consequently, a strong U.S. dollar may adversely affect reported revenues and our profitability.” · word for word
Interest rate exposure on variable debt
“We are also exposed to the risk of increasing interest rates as our revolving credit and term loan facilities are both at a variable interest rate. Any material changes in interest rates could result in higher interest expense and related payments for us.” · word for word
Goodwill impairment risk
“At December 31, 2025, we had $338.3 million of goodwill and other intangible assets, representing approximately 51.6% of our total assets.” · word for word
24 Feb 20268-KCybersecurity incident disclosure; no financial metrics or guidance; material event but limited quantitative impact.open
Risks flagged
Cybersecurity incident with data exfiltration; potential regulatory, legal, and reputational risks; insurance recovery expected but not guaranteed.
“certain files were exfiltrated... evaluating what legal and regulatory notifications and filings may be required... incident has not had a material impact on the Company’s financial systems, operations or financial condition.”
24 Feb 20268-K · 2.02Net sales $603M (+20% y/y); Net sales $149M (+3% y/y); Net income $68M (+16% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $603M | +20% y/y |
| Net sales · Q4-2025 | $149M | +3% y/y |
| Net income · FY2025 | $68M | +16% y/y |
| Net income · Q4-2025 | $18M | +7% y/y |
| Diluted EPS (GAAP) · FY2025 | $8.75 | +15% y/y |
| Diluted EPS (GAAP) · Q4-2025 | $2.25 | +7% y/y |
| Adjusted EBITDA · FY2025 | $121M | +13% y/y |
| Adjusted EBITDA · Q4-2025 | $28M | -7% y/y |
| Medical sales · Medical · FY2025 | $555M | +23% y/y |
| Non-medical sales · Non-medical · FY2025 | $48M | -12% y/y |
Risks flagged
Labor inefficiencies at AJR facility ($6.3M impact in FY2025) due to workforce attrition; Q4 impact reduced to $1.2M but still a headwind.
“absorbing approximately $6.3 million in labor-related inefficiencies at our AJR facility in Illinois...the impact in Q4 dropped to $1.2 million, less than half of the $3.0 million impact in Q3” · word for word
Non-medical sales declining 11.5% indicates weakness in that segment; concentration risk in medical (92% of sales).
“Non-medical sales for 2025 decreased 11.5% to $47.5 million” · word for word
Integration risk from seven acquisitions completed in two years; potential for execution missteps.
“The four acquisitions we completed in 2024 and three we completed in 2025 are all progressing well” · word for word
24 Feb 20268-K · 1.01Amendment No. 27 to Manufacturing Supply Agreement with Intuitive Surgical extends term to 2029, materially increases annual minimum volumes for largest program, adds new program, and includes volume-based pricing.open
Risks flagged
Customer concentration risk remains high as the agreement is with a single strategic customer.
“The Amendment is with Intuitive Surgical SARL, one of the Company’s strategic medical customers.”
Execution risk related to ramping production to meet increased minimum volumes.
“Risks relating to our ability to maintain increased levels of production at profitable levels.” · word for word
13 Feb 20268-K · 5.02Base salary $700,000.00; Annual bonus target 100; LTI target $2Mopen
Figures in the filing · each found in the filing text
| Base salary · FY2026 | $700000.00 | |
| Annual bonus target · FY2026 | 100.0% | |
| LTI target · FY2026 | $2M | |
| One-time RSU grant · FY2026 | $650000.00 |
Risks flagged
CEO transition may cause short-term operational uncertainty
“Appointment of new CEO effective June 4, 2026”
2 Dec 20258-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Leadership transition risk during CEO change, though orderly and internal.
“CEO retirement effective June 2026; new CEO appointed with long tenure at company.”
2 Dec 20258-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Presentation contains forward-looking statements with standard risk factors; no specific new risks identified.
“Certain statements in this presentation may be considered 'forward-looking statements'...subject to risks, uncertainties, and other factors” · word for word
7 Nov 202510-QUFP Technologies reported Q3 2025 results with revenue growth of 6.5% but gross margin decline due to labor disruption; organic sales essentially flat.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $155M | +7% y/y |
| Net sales · 9M-2025 | $454M | +26% y/y |
| Gross margin · Q3-2025 | 27.7% | |
| Gross margin · 9M-2025 | 28.3% | |
| Net income · Q3-2025 | $38M | |
| Net income · 9M-2025 | $51M | |
| Operating cash flow · 9M-2025 | $75M | |
| Long-term debt · 2025-09-30 | $146M |
Risks flagged
Labor disruption risk
“We estimate that the AJR Labor Issue added approximately $3.0 million in incremental labor cost to our cost-of-sales in the third quarter.” · word for word
Tariff cost risk
“Based upon tariffs being passed through by our raw material suppliers, we estimate an increase of approximately $6 million in annual price increases.” · word for word
Customer concentration risk
“Net sales from our largest two customers, Intuitive Surgical SARL and Stryker Corporation, were 27.1% and 17.1% of our total net sales in the three months ended September 30, 2025, respectively.” · word for word
3 Nov 20258-K · 2.02Sales $155M (+6% y/y); Net income $16M (+0% y/y); Adjusted EPS $2.39earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2025 | $155M | +7% y/y |
| Net income · Q3-2025 | $16M | 0% y/y |
| Adjusted EPS · Q3-2025 | $2.39 | |
| MedTech sales · MedTech · Q3-2025 | $142M | +7% y/y |
| Adjusted EBITDA · Q3-2025 | $31M | -5% y/y |
Risks flagged
Labor cost issue at AJR facility impacting margins; expected to improve in Q4.
“roughly $3 million in incremental labor costs at our Illinois AJR facility related to a post-acquisition review of our labor force’s eligibility to work under US laws.” · word for word
UFP Technologies, Inc. — questions
- What did UFP Technologies, Inc. file recently?
- 19 SEC filings in the last 12 months. Latest: 8-K on 2026-08-24 — UFP Technologies filed an 8-K with updated investor presentation materials; no material operational or financial event disclosed.
Every figure on this page comes from UFP Technologies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.